Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Bioinspired exosome-SiO 2 nanohybrid therapeutic for rheumatoid arthritis treatment.

Zhu Q., Chen R., Wu X., Zhou Y., Wang Z., Zhang H.

Animal Study on Chronic Inflammation, Immune Modulation, Autoimmune Research, published in Theranostics (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Theranostics (2025)
Country
Australia
Reported sample size
—
Source database
PubMed
PMID
40521182
PMCID
PMC12160022
DOI
10.7150/thno.108296
Citations
3

Abstract (original English)

Objective: Due to their anti-inflammatory and immunomodulatory capabilities, adipose-derived stem cells (ADSC) are currently considered a promising option for the management of rheumatoid arthritis (RA). To tackle the problems of immunogenicity and tumorigenicity linked to the direct use of cells, current research is focused on the development of effective nanomedicines utilizing ADSC-derived exosomes (ADSC-EXO) for cell-free regenerative medicine. Methods: Methotrexate (MTX) was loaded into mesoporous silica through physical adsorption to produce SiO 2 -MTX, with subsequent incorporation into ADSC-EXO via ultrasonication to produce AE@SiO 2 -MTX. Particle size, surface charge, and stability were characterized using dynamic light scattering (DLS) and zeta potential analysis. In vitro , the effects of the nanomaterials were evaluated by assessing the inverse polarization effect of AE@SiO 2 -MTX on RAW264.7 macrophages, as well as on the migration and invasion capabilities of fibroblast-like synovial cells (FLS). In vivo, targeting and therapeutic effects on joint inflammation were examined using adjuvant-induced arthritis (AIA) and collagen-induced arthritis (CIA) mouse models. Results: The AE@SiO₂-MTX demonstrated sustained drug release, high biocompatibility, and rapid cellular internalization. In vitro , the delivery system alleviated chronic inflammation by inducing macropha

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsSilicon DioxideArthritis, RheumatoidExosomesMiceMethotrexateDisease Models, AnimalTreatment OutcomeStem CellsArthritis, Experimental

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research